Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 05, 2017 11:10 ET | Source: Diffusion Pharmaceuticals, Inc.

Diffusion Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

CHARLOTTESVILLE, Va., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on the...
August 23, 2017 07:30 ET | Source: Diffusion Pharmaceuticals, Inc.

Diffusion Pharmaceuticals Names William Hornung Chief Business Officer

CHARLOTTESVILLE, Va., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on the development...
August 14, 2017 16:01 ET | Source: Diffusion Pharmaceuticals, Inc.

Diffusion Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update

CHARLOTTESVILLE, Va., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on the development...
July 31, 2017 08:30 ET | Source: Diffusion Pharmaceuticals, Inc.

Diffusion Pharmaceuticals Selects Contract Research Organization for Phase 3 Clinical Trial of Lead Compound TSC for Inoperable GBM Brain Cancer

CHARLOTTESVILLE, Va., July 31, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN), a clinical stage biotechnology company developing novel small molecule therapeutics for cancer...
July 20, 2017 08:30 ET | Source: Diffusion Pharmaceuticals, Inc.

Diffusion Pharmaceuticals Achieves Drug Production Milestone For Planned Phase 3 Clinical Trial In Inoperable GBM Brain Cancer

CHARLOTTESVILLE, Va., July 20, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a clinical stage biotechnology company developing novel small molecule therapeutics for cancer...
July 06, 2017 08:00 ET | Source: Diffusion Pharmaceuticals, Inc.

Diffusion Pharmaceuticals Appoints Dr. Robert Ruffolo to Board of Directors

CHARLOTTESVILLE, Va., July 06, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a clinical stage biotechnology company focused on the development of novel small molecule...
May 15, 2017 16:05 ET | Source: Diffusion Pharmaceuticals, Inc.

Diffusion Pharmaceuticals Provides Corporate Highlights and Reports Financial First Quarter 2017 Results

CHARLOTTESVILLE, Va., May 15, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a clinical stage biotechnology company focused on the development of novel small molecule...
April 04, 2017 08:41 ET | Source: Diffusion Pharmaceuticals, Inc.

Diffusion Pharmaceuticals Awarded U.S. Patent for TSC as Therapeutic in Five Hypoxia-Related Indications

CHARLOTTESVILLE, Va., April 04, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a clinical stage biotechnology company focused on the development of novel small molecule...
April 03, 2017 08:30 ET | Source: Diffusion Pharmaceuticals, Inc.

Diffusion Pharmaceuticals Announces Closing of Oversubscribed Private Placement

CHARLOTTESVILLE, Va., April 03, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a clinical stage biotechnology company focused on the development of novel small molecule...
March 31, 2017 08:30 ET | Source: Diffusion Pharmaceuticals, Inc.

Diffusion Pharmaceuticals Provides Corporate Highlights and Reports 2016 Financial Results

CHARLOTTESVILLE, Va., March 31, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a clinical stage biotechnology company focused on the development of novel small molecule...